Why Do Phase III Clinical Trials in Oncology Fail so Often?

被引:39
作者
Amiri-Kordestani, Laleh [1 ]
Fojo, Tito [1 ]
机构
[1] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
DRUG DEVELOPMENT; TARGETED AGENTS; STABLE DISEASE; END-POINT; CHEMOTHERAPY; SURVIVAL; CANCER; BENEFIT; DESIGNS;
D O I
10.1093/jnci/djs180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:568 / 569
页数:2
相关论文
共 19 条
[1]   Drug Development: Portals of Discovery [J].
Bates, Susan E. ;
Amiri-Kordestani, Laleh ;
Giaccone, Giuseppe .
CLINICAL CANCER RESEARCH, 2012, 18 (01) :23-32
[2]  
Berry DA, 2011, NAT REV CLIN ONCOL
[3]   Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies [J].
Booth, Christopher M. ;
Ohorodnyk, Pavlo ;
Eisenhauer, Elizabeth A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :E213-E214
[4]   A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology [J].
Bruno, Rene ;
Lu, Jian-Feng ;
Sun, Yu-Nien ;
Claret, Laurent .
JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (01) :6-8
[5]   Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J].
Buyse, M ;
Thirion, P ;
Carlson, RW ;
Burzykowski, T ;
Molenberghs, G ;
Piedbois, P .
LANCET, 2000, 356 (9227) :373-378
[6]   A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer [J].
Chen, TT ;
Chute, JP ;
Feigal, E ;
Johnson, BE ;
Simon, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19) :1601-1607
[7]   Benefits, challenges and obstacles of adaptive clinical trial designs [J].
Chow, Shein-Chung ;
Corey, Ralph .
ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
[8]   Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics [J].
Claret, Laurent ;
Girard, Pascal ;
Hoff, Paulo M. ;
Van Cutsem, Eric ;
Zuideveld, Klaas P. ;
Jorga, Karin ;
Fagerberg, Jan ;
Bruno, Rene .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4103-4108
[9]   Rapidly rising clinical trial costs worry researchers [J].
Collier, Roger .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2009, 180 (03) :277-278
[10]   Adaptive Methods: Telling "The Rest of the Story" [J].
Emerson, Scott S. ;
Fleming, Thomas R. .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (06) :1150-1165